Jacques de Mouzon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jacques de Mouzon has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Silke Dyer
Department of Obstetrics and Gynaecology, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; African Network and Registry for Assisted Reproductive Technology
4 shared publications A. Devaux
2 shared publications- Fernando Zegers-Hochschild
Program of Ethics and Public Policies in Human Reproduction, Faculty de Medicine, University Diego Portales, Santiago, Chile; Unit of Reproductive Medicine, Clínica Las Condes, Santiago, Chile
2 shared publications - G. David Adamson
Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, USA
2 shared publications - Georgina Mary Chambers
National Perinatal Epidemiology and Statistics Unit, Centre for Big Data Research in Health, University of New South Wales , Sydney
2 shared publications - Nathalie Sermondade
Service de Biologie de la Reproduction CECOS, Hôpital Tenon (AP-HP), Sorbonne-Université 75020 PARIS, France; Sorbonne Université, Centre de recherche Saint-Antoine, Inserm US938 75012 PARIS, France
2 shared publications
Latest Publications
- Top Cited Papers
- 11 February 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (1) , 40-50
How many infants have been born with the help of assisted reproductive technology?
- 11 February 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (1) , 40-50
Top Cited PapersHow many infants have been born with the help of assisted reproductive technology?
- Open Access
- 1 June 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (Supplement)
O-154 ICMART preliminary world report 2019
Title: International Committee for Monitoring Assisted Reproductive Technologies (ICMART) Preliminary World Report on ART, 2019 Study question: In 2019 what was the global utilization, effectiveness and safety of ART? Summary answer: Globally, ART utilization and data collection continue to increase but with wide variations in utilization, effectiveness and safety. What is known already: ICMART began ART global data collection in 1991. Utilization, effectiveness and safety have continuously improved with more cycles, higher pregnancy rates and lower multiple birth rates, the latter due to the transfer of fewer embryos. Frozen embryo transfer (FET) and donor egg cycles continue to increase. However, wide variations in practice and outcomes exist globally. Approximately 10 million ART babies have been born. ICMART has helped develop registries internationally. A new electronic data collection platform has been developed with the University of New South Wales (UNSW) in Sydney, Australia; nevertheless, data collection and quality remain challenging. Study design, size, duration: Countries and regions annually collect ART data, some prospectively and others retrospectively. ICMART retrospectively requested data from all known global sources for 2019 and reviewed them for missing or incorrect data. The dataset was reviewed and corrected by ICMART, in partnership with UNSW for validation and analysis, then ICMART finalized the results tables. Standardized definitions from The International Glossary on Infertility and Fertility Care, 2017, and previously developed methods were used. Preliminary results are presented. Participants/materials, setting, methods: The European IVF Monitoring Consortium (EIM), Latin American Network of Assisted Reproduction (REDLARA), Australian/ New Zealand Registry and African Network and Registry for ART (ANARA) submitted regional data, and other countries contributed national data, through standardized formats, to ICMART. A few individual clinics with no registry access also contributed. Data received were reviewed, corrected, and validated to the extent possible, analyzed and summarized by ICMART using descriptive statistics. Main results and the role of chance: Data collection and analysis are ongoing, so the presented results are preliminary. The number of ART cycles continues to increase, but utilization is still highly variable among countries and regions. Regional and country differences persist in the age of women treated, number of embryos transferred, live birth rates, rate of multiple births, use of ICSI, cryopreservation cycles and other factors. The role of chance is minimal. Actual global ART results are limited to reporting countries and clinics representing 90 to 95% of global cycles. However, this is a very large sample size from which imputation of total global results is performed. Limitations, reasons for caution: Most, but not all, countries report to ICMART. Some countries have limited data and many countries have limited data validation. ICMART can perform only minimal verification of submitted data. Widespread adherence to consensus definitions provided in the Glossary takes time and requires translation into multiple languages. Standardization of validation and reporting is an ongoing process because of missing data and continuing changes in clinical practice. Wider implications of the findings: ICMART World Reports standardize data, track trends, enable comparisons, stimulate questions and improve ART quality. Better understanding of ART increases societal acceptance and support for equitable access and ART research.
- 1 June 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (Supplement)
Open AccessO-154 ICMART preliminary world report 2019
Title: International Committee for Monitoring Assisted Reproductive Technologies (ICMART) Preliminary World Report on ART, 2019 Study question: In 2019 what was the global utilization, effectiveness and safety of ART? Summary answer: Globally, ART utilization and data collection continue to increase but with wide variations in utilization, effectiveness and safety. What is known already: ICMART began ART global data collection in 1991. Utilization, effectiveness and safety have continuously improved with more cycles, higher pregnancy rates and lower multiple birth rates, the latter due to the transfer of fewer embryos. Frozen embryo transfer (FET) and donor egg cycles continue to increase. However, wide variations in practice and outcomes exist globally. Approximately 10 million ART babies have been born. ICMART has helped develop registries internationally. A new electronic data collection platform has been developed with the University of New South Wales (UNSW) in Sydney, Australia; nevertheless, data collection and quality remain challenging. Study design, size, duration: Countries and regions annually collect ART data, some prospectively and others retrospectively. ICMART retrospectively requested data from all known global sources for 2019 and reviewed them for missing or incorrect data. The dataset was reviewed and corrected by ICMART, in partnership with UNSW for validation and analysis, then ICMART finalized the results tables. Standardized definitions from The International Glossary on Infertility and Fertility Care, 2017, and previously developed methods were used. Preliminary results are presented. Participants/materials, setting, methods: The European IVF Monitoring Consortium (EIM), Latin American Network of Assisted Reproduction (REDLARA), Australian/ New Zealand Registry and African Network and Registry for ART (ANARA) submitted regional data, and other countries contributed national data, through standardized formats, to ICMART. A few individual clinics with no registry access also contributed. Data received were reviewed, corrected, and validated to the extent possible, analyzed and summarized by ICMART using descriptive statistics. Main results and the role of chance: Data collection and analysis are ongoing, so the presented results are preliminary. The number of ART cycles continues to increase, but utilization is still highly variable among countries and regions. Regional and country differences persist in the age of women treated, number of embryos transferred, live birth rates, rate of multiple births, use of ICSI, cryopreservation cycles and other factors. The role of chance is minimal. Actual global ART results are limited to reporting countries and clinics representing 90 to 95% of global cycles. However, this is a very large sample size from which imputation of total global results is performed. Limitations, reasons for caution: Most, but not all, countries report to ICMART. Some countries have limited data and many countries have limited data validation. ICMART can perform only minimal verification of submitted data. Widespread adherence to consensus definitions provided in the Glossary takes time and requires translation into multiple languages. Standardization of validation and reporting is an ongoing process because of missing data and continuing changes in clinical practice. Wider implications of the findings: ICMART World Reports standardize data, track trends, enable comparisons, stimulate questions and improve ART quality. Better understanding of ART increases societal acceptance and support for equitable access and ART research.
- Open Access
- 2 April 2023
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 46 (4)
Contents
- 2 April 2023
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 46 (4)
Open AccessContents
- Open Access
- 30 November 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (11) , e1003857
Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: A national retrospective cohort study
Background: To the best of our knowledge, no study has exhaustively evaluated the association between maternal morbidities and Coronavirus Disease 2019 (COVID-19) during the first wave of the pandemic in pregnant women. We investigated, in natural conceptions and assisted reproductive technique (ART) pregnancies, whether maternal morbidities were more frequent in pregnant women with COVID-19 diagnosis compared to pregnant women without COVID-19 diagnosis during the first wave of the COVID-19 pandemic. Methods and findings: We conducted a retrospective analysis of prospectively collected data in a national cohort of all hospitalizations for births ≥22 weeks of gestation in France from January to June 2020 using the French national hospitalization database (PMSI). Pregnant women with COVID-19 were identified if they had been recorded in the database using the ICD-10 (International Classification of Disease) code for presence of a hospitalization for COVID-19. A total of 244,645 births were included, of which 874 (0.36%) in the COVID-19 group. Maternal morbidities and adverse obstetrical outcomes among those with or without COVID-19 were analyzed with a multivariable logistic regression model adjusted on patient characteristics. Among pregnant women, older age (31.1 (±5.9) years old versus 30.5 (±5.4) years old, respectively, p < 0.001), obesity (0.7% versus 0.3%, respectively, p < 0.001), multiple pregnancy (0.7% versus 0.4%, respectively, p < 0.001), and history of hypertension (0.9% versus 0.3%, respectively, p < 0.001) were more frequent with COVID-19 diagnosis. Active smoking (0.2% versus 0.4%, respectively, p < 0.001) and primiparity (0.3% versus 0.4%, respectively, p < 0.03) were less frequent with COVID-19 diagnosis. Frequency of ART conception was not different between those with and without COVID-19 diagnosis (p = 0.28). When compared to the non-COVID-19 group, women in the COVID-19 group had a higher frequency of admission to ICU (5.9% versus 0.1%, p < 0.001), mortality (0.2% versus 0.005%, p < 0.001), preeclampsia/eclampsia (4.8% versus 2.2%, p < 0.001), gestational hypertension (2.3% versus 1.3%, p < 0.03), postpartum hemorrhage (10.0% versus 5.7%, p < 0.001), preterm birth at p < 0.001), p < 0.001), p < 0.001), induced preterm birth (5.4% versus 1.4%, p < 0.001), spontaneous preterm birth (11.3% versus 5.7%, p < 0.001), fetal distress (33.0% versus 26.0%, p < 0.001), and cesarean section (33.0% versus 20.2%, p < 0.001). Rates of pregnancy terminations ≥22 weeks of gestation, stillbirths, gestational diabetes, placenta praevia, and placenta abruption were not significantly different between the COVID-19 and non-COVID-19 groups. The number of venous thromboembolic events was too low to perform statistical analysis. A limitation of this study relies in the possibility that asymptomatic infected women were not systematically detected. Conclusions: We observed an increased frequency of pregnant women with maternal morbidities and diagnosis of COVID-19 compared to pregnant women without COVID-19. It appears essential to be aware of this, notably in populations at known risk of developing a more severe form of infection or obstetrical morbidities and in order for obstetrical units to better inform pregnant women and provide the best care. Although causality cannot be determined from these associations, these results may be in line with recent recommendations in favor of vaccination for pregnant women.
- 30 November 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (11) , e1003857
Open AccessObstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: A national retrospective cohort study
Background: To the best of our knowledge, no study has exhaustively evaluated the association between maternal morbidities and Coronavirus Disease 2019 (COVID-19) during the first wave of the pandemic in pregnant women. We investigated, in natural conceptions and assisted reproductive technique (ART) pregnancies, whether maternal morbidities were more frequent in pregnant women with COVID-19 diagnosis compared to pregnant women without COVID-19 diagnosis during the first wave of the COVID-19 pandemic. Methods and findings: We conducted a retrospective analysis of prospectively collected data in a national cohort of all hospitalizations for births ≥22 weeks of gestation in France from January to June 2020 using the French national hospitalization database (PMSI). Pregnant women with COVID-19 were identified if they had been recorded in the database using the ICD-10 (International Classification of Disease) code for presence of a hospitalization for COVID-19. A total of 244,645 births were included, of which 874 (0.36%) in the COVID-19 group. Maternal morbidities and adverse obstetrical outcomes among those with or without COVID-19 were analyzed with a multivariable logistic regression model adjusted on patient characteristics. Among pregnant women, older age (31.1 (±5.9) years old versus 30.5 (±5.4) years old, respectively, p < 0.001), obesity (0.7% versus 0.3%, respectively, p < 0.001), multiple pregnancy (0.7% versus 0.4%, respectively, p < 0.001), and history of hypertension (0.9% versus 0.3%, respectively, p < 0.001) were more frequent with COVID-19 diagnosis. Active smoking (0.2% versus 0.4%, respectively, p < 0.001) and primiparity (0.3% versus 0.4%, respectively, p < 0.03) were less frequent with COVID-19 diagnosis. Frequency of ART conception was not different between those with and without COVID-19 diagnosis (p = 0.28). When compared to the non-COVID-19 group, women in the COVID-19 group had a higher frequency of admission to ICU (5.9% versus 0.1%, p < 0.001), mortality (0.2% versus 0.005%, p < 0.001), preeclampsia/eclampsia (4.8% versus 2.2%, p < 0.001), gestational hypertension (2.3% versus 1.3%, p < 0.03), postpartum hemorrhage (10.0% versus 5.7%, p < 0.001), preterm birth at p < 0.001), p < 0.001), p < 0.001), induced preterm birth (5.4% versus 1.4%, p < 0.001), spontaneous preterm birth (11.3% versus 5.7%, p < 0.001), fetal distress (33.0% versus 26.0%, p < 0.001), and cesarean section (33.0% versus 20.2%, p < 0.001). Rates of pregnancy terminations ≥22 weeks of gestation, stillbirths, gestational diabetes, placenta praevia, and placenta abruption were not significantly different between the COVID-19 and non-COVID-19 groups. The number of venous thromboembolic events was too low to perform statistical analysis. A limitation of this study relies in the possibility that asymptomatic infected women were not systematically detected. Conclusions: We observed an increased frequency of pregnant women with maternal morbidities and diagnosis of COVID-19 compared to pregnant women without COVID-19. It appears essential to be aware of this, notably in populations at known risk of developing a more severe form of infection or obstetrical morbidities and in order for obstetrical units to better inform pregnant women and provide the best care. Although causality cannot be determined from these associations, these results may be in line with recent recommendations in favor of vaccination for pregnant women.
- Open Access
- 1 September 2021
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 22 (3) , 235-241
The experience of in vitro fertilization data collection in Turkey
Collecting and reporting data is a crucial aspect of IVF practice. During the following two decades after the first report of European IVF-monitoring Consortium (EIM) on IVF data, the number of contributing countries increased gradually reaching nearly fourty. In 2004 for the first time Turkey took part in European registry and accordingly in World registry. Starting the submission of Turkish data to EIM was an important milestone since Turkey appeared as the sixth country in relation to the number of cycles performing nearly eight percent of all European ART cycles. Turkey continued contributing to European registry for the following four years consecutively but after 2008 the input of Turkish IVF data stopped again. Strikingly, between 2004-2008 Turkey became one of the main contributors of the registry with an ability to give a full report. So far, we do not have a complete European set of data and the number of cycles reported by ESHRE EIM can easily be said to be an underestimation of the actual number of cycles. The IVF data of Turkey - a country having the seventeenth highest population in the World and appearing among the first six countries in Europe in terms of the number of ART cycles per year- will definitely contribute very much to ESHRE EIM database. Then, it is time to turn the tide and restart submitting the data to European registry, but this time regularly in a systematic method. Such an achievement will greatly contribute to the aim of EIM of achieving a complete data set.
- 1 September 2021
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 22 (3) , 235-241
Open AccessThe experience of in vitro fertilization data collection in Turkey
Collecting and reporting data is a crucial aspect of IVF practice. During the following two decades after the first report of European IVF-monitoring Consortium (EIM) on IVF data, the number of contributing countries increased gradually reaching nearly fourty. In 2004 for the first time Turkey took part in European registry and accordingly in World registry. Starting the submission of Turkish data to EIM was an important milestone since Turkey appeared as the sixth country in relation to the number of cycles performing nearly eight percent of all European ART cycles. Turkey continued contributing to European registry for the following four years consecutively but after 2008 the input of Turkish IVF data stopped again. Strikingly, between 2004-2008 Turkey became one of the main contributors of the registry with an ability to give a full report. So far, we do not have a complete European set of data and the number of cycles reported by ESHRE EIM can easily be said to be an underestimation of the actual number of cycles. The IVF data of Turkey - a country having the seventeenth highest population in the World and appearing among the first six countries in Europe in terms of the number of ART cycles per year- will definitely contribute very much to ESHRE EIM database. Then, it is time to turn the tide and restart submitting the data to European registry, but this time regularly in a systematic method. Such an achievement will greatly contribute to the aim of EIM of achieving a complete data set.
- 1 July 2020
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 41 (1) , 6-9
ART utilization: an indicator of access to infertility care
- 1 July 2020
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 41 (1) , 6-9
ART utilization: an indicator of access to infertility care
- Open Access
- 1 January 2020
- Published by Open Access Text Pvt, Ltd. in Clinical Obstetrics, Gynecology and Reproductive Medicine
- Vol. 6 (1)
Using high magnification to select sperm: a large prospective cohort study comparing ICSI and IMSI
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 January 2020
- Published by Open Access Text Pvt, Ltd. in Clinical Obstetrics, Gynecology and Reproductive Medicine
- Vol. 6 (1)
Open AccessUsing high magnification to select sperm: a large prospective cohort study comparing ICSI and IMSI
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 February 2019
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 38 (2) , 216-224
Assisted reproductive technologies in Africa: first results from the African Network and Registry for Assisted Reproductive Technology, 2013
- 1 February 2019
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 38 (2) , 216-224
Assisted reproductive technologies in Africa: first results from the African Network and Registry for Assisted Reproductive Technology, 2013
- 1 November 2014
- Published by Elsevier in Fertility and Sterility
- Vol. 102 (5) , 1268-1273
High body mass index has a deleterious effect on semen parameters except morphology: results from a large cohort study
- 1 November 2014
- Published by Elsevier in Fertility and Sterility
- Vol. 102 (5) , 1268-1273
High body mass index has a deleterious effect on semen parameters except morphology: results from a large cohort study
- 1 September 2004
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 32 (9) , 730-736
La femme de 40 ans et plus en FIV et en ICSI : données FIVNAT
- 1 September 2004
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 32 (9) , 730-736
La femme de 40 ans et plus en FIV et en ICSI : données FIVNAT